Navigation Links
BerGenBio Presents New Data Demonstrating That BGB324 Enhances Checkpoint Inhibitor Blockade

BERGEN, Norway, April 18, 2016 /PRNewswire/ --

BerGenBio AS ("BerGenBio" or the "Company") announces that preclinical data demonstrating that lead compound, BGB324, combined with immune checkpoint inhibitors has the potential to synergistically improve treatment of human cancers, has been presented at the American Association of Cancer Research Annual Meeting (AACR), April 16-20, 2016 in New Orleans, Louisiana.

BGB324 is a first-in-class, highly selective, orally bioavailable small molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition (EMT), which is a key driver in immune evasion, drug-resistance and metastasis.

The poster presentation entitled: "BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy", was held on Sunday April 17, 2016, 1:00 PM - 5:00 PM CDT as part of the session on Immune Modulating Agents 1. The data demonstrates that selective inhibition of Axl signalling with BGB324 significantly increased responsiveness to immune checkpoint blockade in syngeneic mammary and lung cancer mouse models. It was found that the combination of BGB324 with different immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PD-L1) displayed increased infiltration of cytotoxic T lymphocytes and natural killer cells and significantly improved anti-tumour responses.

The full abstract (#566) can be viewed online through the AACR website at

Richard Godfrey, Chief Executive Officer of BerGenBio, commented:

"We are pleased with the encouraging preclinical data on BGB324 presented at the annual AACR meeting. Whilst BGB324 is currently in clinical trials as a single agent and in combination with standard of care drug in acute myeloid leukaemia, and in combination with erlotinib in non-small cell lung cancer; this data suggests it also has the potential to be used in combination with immune checkpoint inhibitors, an important emerging class of anti-cancer drug, to enhance their efficacy."

About BerGenBio AS 

BerGenBio AS is a clinical stage biopharmaceutical company focused on developing first-in-class drugs for aggressive cancers. The company is a world leader in understanding the biology of epithelial-mesenchymal transition (EMT), a widely recognised key pathway in immune evasion, acquired cancer drug-resistance and metastasis. BerGenBio AS is founded on proprietary platform technology, CellSelect™, to identify and validate novel drug targets and biomarkers. The company has progressed its lead drug candidate BGB324, an EMT inhibitor, into clinical trials in AML and NSCLC, while pursuing the pre-clinical development of additional compounds and proprietary EMT drug targets.

Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. BerGenBio Awarded 2015 Nordic Stars Award
2. BerGenBio Appoints Non-Executive Directors
3. BerGenBio Initiates NSCLC Clinical Trial With BGB324 in Combination With erlotinib
4. BerGenBio Completes NOK90 Million Fundraising
5. BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award
6. Omnicell presents the pro forma financial information related to its acquisition of Aesynt
7. Samumed Presents At The Annual Meeting Of The American Academy Of Dermatology (AAD) Safety And Efficacy Results From Its Phase 2 Androgenetic Alopecia (AGA) Trial
8. Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting
9. NxStage Presents New Findings on Lowering HHD Attrition Through Nx2me Connected Health Technology and Increased Training Volume
10. AcelRx Pharmaceuticals Presents Phase 3 Results from ARX-04 Clinical Program at JAB Burn and Wound Care Symposium
11. Bayer Presents Latest Xofigo (radium Ra 223 dichloride) Injection Research at ASCO GU 2016
Post Your Comments:
(Date:3/27/2020)... ... ... Why a Podcast for Procap Medical Billing? , One of the main ... to explain more about what her business entails on a regular basis. There are ... the process of claim follow-up, conversing and networking with health care companies, and attaining ...
(Date:3/22/2020)... ... March 21, 2020 , ... ... University Hospital (TUH), its Department of Thoracic Medicine and Surgery, and the Temple ... HGE Health’s COVID Care symptom tracking platform and triage/care coordination services. Temple is ...
(Date:3/20/2020)... ... March 20, 2020 , ... Today, in response to Maryland ... the COVID-19 public health emergency, Mercy Medical Center sought and received an ... new 32-bed acute care unit on the 17th floor of the hospital’s main inpatient ...
Breaking Medicine Technology:
(Date:3/28/2020)... VALLEY, N.Y. (PRWEB) , ... March 27, 2020 ... ... to protect workers and the public from the spread of the coronavirus. Operating ... Cuomo, crews are pressing forward with infrastructure renewal and environmental protection projects in ...
(Date:3/27/2020)... ... March 27, 2020 , ... Justin P. Kubeck, ... Docs. Dr. Kubeck has been approved every year consecutively since 2016. Dr. Kubeck ... Spinal Surgery. , Dr. Kubeck’s medical education began at Thomas Jefferson University. ...
(Date:3/22/2020)... ... 2020 , ... In partnership with UC Health, Cincy Shirts has created a ... first responders. The title comes from the English translation of “Juncta Juvant”, the City ... , Proceeds from the sale of the shirt will benefit the YMCA of Cincinnati ...
(Date:3/20/2020)... ... 20, 2020 , ... CommunityMed Urgent Care , based in Dallas, has ... room lets patients present online, complete registration paperwork (including the latest COVID screening) provide ... and get signaled that their clean exam room is ready. All of this ...
(Date:3/19/2020)... ... March 19, 2020 , ... Sucheta Kamath, Founder and CEO ... free Student Learning Exercise: ExQ® Superpower Hour. During the recent closure ... to help with the immediate need for activities that can be implemented at ...
Breaking Medicine News(10 mins):